News Celularity Inc.

Equities

CELU

US1511902041

Delayed Nasdaq Other stock markets 17:19:06 29/04/2024 BST			5-day change	1st Jan Change
3.021 ^USD	+0.05%		-1.26%	+22.13%

03-26	Celularity Receives Healthcare Common Procedure Coding System Q Code Approval from the U.S. Centers for Medicare & Medicaid Services for Biovance 3L	CI
03-20	Celularity Seeks FDA Orphan Drug Status for PDA-002 in Facioscapulohumeral Muscular Dystrophy	MT

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Celularity Inc. to Host Investor and Analyst Research and Development Day	04-23	AQ
Celularity Inc. Announces Receipt of Nasdaq Notice Regarding Late Form 10-K Filing	04-22	AQ
Celularity Inc. to Host Investor and Analyst Research & Development Day	04-22	AQ
Celularity Inc. Announces Receipt of Nasdaq Notice Regarding Late Form 10-K Filing	04-19	AQ
Celularity Abstract “Emerging Technologies for the Management and Protection of Tendon Injuries: Decellularized Placental Biomaterials” Accepted at ORS Tendon Conference 2024	04-18	AQ
Celularity Announces Net Sales Trending Ahead of Expectations for First Quarter 2024, Implements Planned 2024 SG&A Reductions and Manufacturing Ramp for Advanced Biomaterial Products	04-16	AQ
Celularity Announces Net Sales Trending Ahead of Expectations for First Quarter 2024; Implements Planned 2024 SG&A Reductions and Manufacturing Ramp for Advanced Biomaterial Products	04-15	AQ
Celularity to Present Data Showing Senescent Cell Elimination by Off-the-Shelf Natural Killer Cells Derived from Human Placental Cells	04-08	AQ
Celularity Receives Healthcare Common Procedure Coding System (HCPCS) Q Code Approval from the U.S. Centers for Medicare & Medicaid Services for Biovance® 3L	03-26	AQ
Celularity Receives Healthcare Common Procedure Coding System Q Code Approval from the U.S. Centers for Medicare & Medicaid Services for Biovance 3L	03-26	CI
Celularity Seeks FDA Orphan Drug Status for PDA-002 in Facioscapulohumeral Muscular Dystrophy	03-20	MT
Celularity Submits Request to U.S. FDA for Orphan Drug Designation for PDA-002 Asset Treating Facioscapulohumeral Muscular Dystrophy	03-20	AQ
Celularity CEO to Present on Cell Therapy’s Potential to Improve Longevity at 2024 ABUNDANCE Summit	03-14	AQ
Celularity Inc. announced that it expects to receive $10 million in funding from Yorkville Advisors Global LP	03-12	CI
Celularity CEO to Present Keynote Address at 2024 Society for Brain Mapping and Therapeutics Annual World Congress	03-12	AQ
Celularity to Present Data Showing Cancer Tumor Reduction by Off-the-Shelf Cell Therapy Derived from Human Placental Cells	03-07	AQ
Celularity to Execute Reverse Stock Split Next Week	02-23	MT
Celularity Announces 1-for-10 Reverse Stock Split	02-23	AQ
Celularity’s Tri-layer Decellularized, Dehydrated Human Amniotic Membrane Product Investigated as a Carrier of Induced Pluripotent Stem Cell Derived-Limbal Stem Cells in the Treatment of Severe Ocular Surface Disease	02-14	AQ
Celularity Announces Net Sales Expectations for First Quarter 2024 and Full Year 2024, Reiterates Advanced Biomaterial Product Commercial and Development Pipeline	02-01	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Celularity Inc.

Equities

CELU

US1511902041

Summary

Filters